Page last updated: 2024-11-02

pd 169316 and Parkinsonian Disorders

pd 169316 has been researched along with Parkinsonian Disorders in 1 studies

2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zawada, WM1
Meintzer, MK1
Rao, P1
Marotti, J1
Wang, X1
Esplen, JE1
Clarkson, ED1
Freed, CR1
Heidenreich, KA1

Other Studies

1 other study available for pd 169316 and Parkinsonian Disorders

ArticleYear
Inhibitors of p38 MAP kinase increase the survival of transplanted dopamine neurons.
    Brain research, 2001, Feb-09, Volume: 891, Issue:1-2

    Topics: Animals; Brain Tissue Transplantation; Cell Survival; Cells, Cultured; Dopamine; Enzyme Inhibitors;

2001